{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:16:20Z","timestamp":1790900180038,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1097\/cco.0b013e3283380939","type":"journal-article","created":{"date-parts":[[2010,4,7]],"date-time":"2010-04-07T00:29:10Z","timestamp":1270600150000},"page":"263-267","source":"Crossref","is-referenced-by-count":56,"title":["Update on castrate-resistant prostate cancer: 2010"],"prefix":"10.1097","volume":"22","author":[{"given":"Kiran","family":"Lassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy A","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-17-20210128","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/SPC.0b013e32830c48a3","article-title":"Systemic therapy after first line docetaxel in metastatic castration-resistant prostate cancer.","volume":"2","author":"Beardsley","year":"2008","journal-title":"Curr Opin Support Palliat Care"},{"key":"R4-17-20210128","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncr.22811","article-title":"Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone","volume":"110","author":"Rosenberg","year":"2007","journal-title":"Cancer"},{"key":"R5-17-20210128","doi-asserted-by":"crossref","first-page":"8724","DOI":"10.1200\/JCO.2005.02.4448","article-title":"Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111","volume":"23","author":"Hussain","year":"2005","journal-title":"J Clin Oncol"},{"key":"R10-17-20210128","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP 17 with abiraterone acetate is highly active in the treatment of castrate-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J Clin Oncol"},{"key":"R12-17-20210128","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J Clin Oncol"},{"key":"R17-17-20210128","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.5138","article-title":"Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) abstr 5138","volume":"27","author":"Slovin","year":"2009","journal-title":"J Clin Oncol"},{"key":"R19-17-20210128","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-07-1506","article-title":"Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer","volume":"13","author":"Danila","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R20-17-20210128","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1158\/1078-0432.CCR-06-2701","article-title":"Circulating tumor cell analysis in patients with progressive castration resistant prostate cancer.","volume":"13","author":"Shaffer","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R21-17-20210128","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.","volume":"14","author":"De Bono","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R23-17-20210128","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0022-5347(01)61829-9","article-title":"Neutralizing antivascular endothelial growth inhibits further growth of established prostate cancer and metastases in a preclinical model","volume":"161","author":"Melynk","year":"1999","journal-title":"J Urol"},{"key":"R24-17-20210128","first-page":"1096","article-title":"Giuliano combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.","volume":"1089-","author":"Di Lorenzo","year":"54","journal-title":"Eur Urol"},{"key":"R26-17-20210128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-07-1355","article-title":"A phase II clinical trial of sorafenib in androgen-independent prostate cancer","volume":"14","author":"Dahut","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R27-17-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.urolonc.2008.06.003","article-title":"Safety and efficacy of sorafenib with castrate resistant prostate cancer.","volume":"28","author":"Safarenijad","year":"2008","journal-title":"Urologic Oncol"},{"key":"R28-17-20210128","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/j.1464-410X.2008.08327.x","article-title":"Final analysis of a phase II trial using sorafenib in castrate resistant prostate cancer.","volume":"103","author":"Aragon-Ching","year":"2009","journal-title":"BJU Int"},{"key":"R29-17-20210128","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1593\/neo.06388","article-title":"Endothelin receptor A blockade enhances taxane effects in prostate cancer","volume":"8","author":"Akhavan","year":"2006","journal-title":"Neoplasia"},{"key":"R30-17-20210128","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nm0995-944","article-title":"Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate","volume":"1","author":"Nelson","year":"1995","journal-title":"Nat Med"},{"key":"R31-17-20210128","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/cncr.22996","article-title":"A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer","volume":"110","author":"Carducci","year":"2007","journal-title":"Cancer"},{"issue":"18S","key":"R32-17-20210128","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1200\/jco.2007.25.18_suppl.5018","article-title":"Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer","volume":"25","author":"Nelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"R33-17-20210128","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.eururo.2008.11.002","article-title":"Safety and efficacy of the specific endothelin A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic: a double-blind, placebo-controlled, randomized, phase 2 trial","volume":"55","author":"James","year":"2008","journal-title":"Eur Urology"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e3283380939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:10:20Z","timestamp":1620951020000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201005000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e3283380939","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}